Biliary tract cancers (BTC) include intra-and extra-hepatic cholangiocarcinoma, as well as gallbladder cancers. 1 BTC are rare and chemoresistant with a universally poor prognosis. 2 The majority of patients present with advanced or metastatic disease at the time of diagnosis, where based off ABC-02, the standard therapy for untreated advanced biliary tract cancer (ABTC) consists of a weekly combination of gemcitabine and cisplatin chemotherapy (GC) administered for a maximum of 8 cycles. 3 A recent study suggested that patients may derive benefit from continued therapy beyond 8 weeks and until the time of disease progression. 4 In the ABC-02 trial, >25% of patients in the GC arm experienced grade 3 or 4 neutropenia, with over 70% of the patients experiencing any grade 3 or 4 adverse effect. Alternative dosing and schedule strategies were shown to optimize drug efficacy while improve tolerability. [5] [6] [7] [8] [9] The administration of gemcitabine at a fixed dose rate (FDR) at 10 mg/m 2 /min allows for the greatest intracellular intracellular accumulation of the active triphosphate form. 10, 11 Previous studies have shown that a biweekly schedule of FDR gemcitabine combination therapy may improve the toxicity profile while adding convenience and maintaining therapeutic efficacy. 12 Based on all the information above, we adopted a modified biweekly regimen of FDR gemcitabine with cisplatin applied for all BTC patients treated with this regimen in our institution. Herein, we report our experienced with biweekly GC in patients with ABTC, including an evaluation of patient tolerability, toxicities and progression-free survival and overall survival (OS).
Material and Methods

Patients and study design
The protocol of this study was reviewed and approved by The Ohio State University Institutional Review Board. Data were obtained from a prospectively collected database for patients who received FDR GC at our institution from January 1, 2010 to December 31, 2015. All patients included in the study had to be older than 18 years of age and had received a histopathologic or cytologic diagnosis of nonresectable, recurrent, or metastatic biliary tract carcinoma (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer or ampullary carcinoma) and an Eastern Cooperative Group (ECOG) performance status of 0-2. Demographics, patient characteristics and toxicities were summarized using descriptive statistics. Progression free survival (PFS) was defined as the time of treatment selection to disease progression or death. Patients were censored if there was no progression at the time of last clinic follow-up. OS was defined as the time from the time of treatment selection to the time of death. Patients were censored if they were alive at the time of last clinic follow-up. PFS and OS curves were estimated using the Kaplan-Meier method and compared by the log-rank test. Toxicity incidence is reported for informative purposes only. 
Results
Patient characteristics
A total of 107 evaluable patients were included in this analysis. The median age was 60 years (range 28-86). Baseline patient and tumor characteristics are presented in Table 1 . The majority of patients (84.1%) had metastatic disease with a median of 1 metastatic site (range 0-3). In regards to anatomic location, most patients had primary bile duct origin (74.8%), followed by gallbladder (21.5%), and ampullary cancer (3.7%).
Efficacy analysis
The median PFS was 8.34 months [95% confidence interval (CI): (6.74, 9.23)] and OS was 10.32 months [95% CI: 9.10,
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Patients diagnosed with biliary tract cancer frequently present with advanced or metastatic disease, for which standard treatment entails an eight-week-long course of weekly administration of combined gemcitabine-cisplatin (GC) chemotherapy. Here, a modified biweekly regimen of GC chemotherapy was examined as a means of potentially optimizing treatment for advanced biliary cancer. Despite a prolonged treatment course, with a median of six biweekly treatment cycles, the modified regimen was associated with minimal toxicities. Median overall survival was just over 10 months. The findings suggest that biweekly GC administration can reduce treatment-related toxicities, while maintaining clinical efficacy and allowing for continued treatment. Cancer Therapy and Prevention
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.43] ( Fig. 1 ; Table 2 ). The response rate for these patients was 16.8%, with a tumor control (complete response, partial response, or stable disease) of 80.4%. Fifty-two percent of the patients went on to receive second line therapy. Patients received a median of 6 cycles (range 1-27). In patients who underwent genomic sequencing, we identified three patients as having germline BRCA mutations (1 BRCA1, 2 BRCA2).
In the three patients who were identified as having germline BRCA mutations, a median PFS of 30.11 months (22.80, 37.42) and a median OS of 59.14 months were observed (Fig.  2) . One patient experienced a partial response, while the other two patients experienced prolonged stable disease.
Toxicities
All adverse reactions were graded according to the National Cancer Institute Common Toxicity Criteria (version 4.0).
Patients had blood draws at days 1 and 15 of every 28-day cycle. Most common grade 3 or 4 toxicities included neutropenia (11%), fatigue (10%), thrombocytopenia (6.4%), anemia (2.8%) and abnormal liver function tests (2.8%) ( Table 2) .
Discussion
BTC remains challenging with universally poor outcomes, with a standardized treatment regimen of gemcitabine and cisplatin (GC). 3 The associated cumulative toxicities and related adverse effects from GC may limit its administration and the ability to provide effective subsequent lines of therapy. In the ABC-02 trial, GC was administered for a maximum of 8 cycles. 3 Biweekly chemotherapy regimens have proven to be a more tolerable treatment strategy while maintaining effectiveness across gastrointestinal malignancies including biliary, pancreatic, and colon cancer. [5] [6] [7] [8] 12, 13 Furthermore, the FDR administration of gemcitabine allows for the greatest intracellular accumulation of the active triphosphate, potentially enhancing the antitumor efficacy of gemcitabine. Thus, these two primary factors helped support the rationale for administering a biweekly schedule in which cisplatin and FDR 
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gemcitabine were administered at the approved standard dose on days 1 and 15 of a 28-day cycle until disease progression, with the goals of improving treatment-related toxicities while maintaining efficacy. Findings from our institutional experience with a very large cohort of patients demonstrated that modified biweekly GC maintained relative effectiveness with clinical outcomes comparable to those historically observed with weekly dosing. The modified dosing schedule was well tolerated and resulted in modest grade 3 and 4 adverse events, with neutropenia (11%) being the most common. In addition to the added convenience, the improved toxicity profile allowed for the biweekly regimen to be administered until disease progression, including one patient who received 27 cycles of therapy with minimal adverse effects. In a disease with limited treatment options and no approved therapies in the refractory setting, the biweekly dosing schedule allowed patients to obtain the potential maximal clinical benefit from the combination without having to experience the associated toxicities with weekly dosing, until disease progression. A small cohort of patients on our study did experience a significant benefit from continued platinum chemotherapy administration, including those with documented BRCA mutations (Fig. 2) . [14] [15] [16] Tumor genomic profiling studies in BTC have shown that a significant proportion of BTC (upwards of 20%) express loss of function mutations in genes associated with DNA repair. This is the highest proportion of DNA repair mutations seen in any gastrointestinal cancer. Thus, patients whose tumors express loss of function of genes associated with DNA repair or homologous recombinant deficiency (HRD), who would likely benefit from continuous cytotoxic chemotherapy that induces DNA damage. Furthermore, the biweekly regimen may be a more preferred strategy to be integrated in future clinical trials examining the role of novel targeted therapies in combination with chemotherapy. 17, 18 Principle limitations to interpreting the results of our study include its retrospective nature, its limited although large sample size and the referral center potential effect on selection bias. However, we believe that the included patient population represents a "real world population" with most deemed non-candidates for enrollment unto clinical trials. While our findings were similar to those seen historically with gemcitabine platinum based chemotherapy in BTC, differences in anatomic subgroup distribution may have influenced our findings, where certain anatomic subgroups may respond more favorably to systemic chemotherapy. To our knowledge, this is the largest study investigating the efficacy and toxicity profile of continuous biweekly gemcitabine and cisplatin in BTC.
A modified biweekly regimen of FDR gemcitabine with cisplatin in the treatment of ABTC holds promise. The utilization of the biweekly administration minimizes cumulative toxicities, which may allow patients to tolerate treatment in addition to receiving further effective therapies in the refractory setting. A recent phase II study (clinicaltrials.gov, NCT02392637) examined the combination of weekly gemcitabine, cisplatin, and nab-paclitaxel (GAC) in ABTC, where patients received the combination until disease progression or intolerance. While the combination demonstrated significant activity, the weekly dosing schedule results in significant hematologic toxicities, with 15% of patients (4 of 27) experiencing grade 3 or higher hematologic toxicities. 19 Further prospective exploration should consider evaluating the role of biweekly gemcitabine based chemotherapy regimens including biweekly GAC in ABTC especially as a potential more favorable platform to combine with novel agents. 
